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Abstract. Background/Aim: We previously reported the
crucial roles of oncogenic Kirsten rat sarcoma viral oncogene
homologue (KRAS) in inhibiting apoptosis and disrupting cell
polarity via the regulation of phosphodiesterase type 4B2
(PDE4B2) expression in human colorectal cancer (CRC)
HCT116 cells in a three-dimensional culture (3DC). Here, we
evaluated the effects of apremilast, a selective PDE4 inhibitor,
on luminal apoptosis in 3DC and nude mice assay using HKe3
human CRC cells stably expressing wild-type (wt)PDE4B2
(HKe3-wtPDE4B2), mutant (mt)PDE4B2 (kinase dead)
(HKe3-wtKRAS), wtKRAS (HKe3-wtKRAS) and mtKRAS
(HKe3-mtKRAS). Materials and Methods: Apoptosis was
detected by immunofluorescence using confocal laser scanning
microscopy or western blot in HKe3-wtPDE4B2, HKe3-
mtPDE4B2, HKe3-wtKRAS and mtKRAS cells treated with or
without apremilast in 3DC. Tumourigenicity was assessed in
nude mice assay using these cells. Results: Apremilast did not
inhibit the proliferation of HKe3-wtPDE4B2 cells or HKe3-
mtKRAS in two-dimensional cultures, whereas the number of
apoptotic HKe3-wtPDE4B2 cells and HKe3-mtKRAS cells
increased after apremilast treatment in 3DC, leading to
formation of a luminal cavity. Tumour growth in nude mice
was dramatically reduced by intraperitoneal injection of
apremilast. Notably, a decreased level of caspase-1 expression
was observed in HKe3-wtPDE4B2 and HKe3-mtKRAS cells.
Conclusion: Apremilast induces tumour regression in nude
mice, possibly by inducing caspase-1 expression.
The impairment of cyclic AMP (cAMP) generation by
overexpression of phosphodiesterase 4 (PDE4) isoforms,
including PDE4A, PDE4B, PDE4C and PDE4D (1, 2), has
been described in various cancer pathologies (3). Indeed,
many recent studies have indicated that PDE4 inhibitors are
effective against different types of cancer cells (4-9). In our
recent studies, we found that PDE4B is specifically up-
regulated by mutated Kirsten rat sarcoma viral oncogene
homologue (KRAS) in three-dimensional (3D) culture, and
PDE4 inhibitors, including rolipram and resveratrol, were
found to induce luminal apoptosis of human colorectal
cancer cells with mutated KRAS in 3D culture (10, 11),
suggesting that PDE4 is a novel effector protein downstream
of mutated KRAS signaling within the in vivo
microenvironment. Currently, there are no effective drugs
that directly target effectors of KRAS signaling or mutated
KRAS in clinical use. Therefore, PDE4 inhibitors may
provide a novel strategy for targeting different types of
cancer cells with mutated KRAS, including colorectal and
pancreatic cancers.
Apremilast, an oral small molecule inhibitor of PDE4, is
approved by the United States Food and Drug Administration
for treating patients with chronic inflammatory disorders,
such as psoriasis and psoriatic arthritis (12, 13). Notably,
apremilast shows favourable adverse reaction profiles
compared to other PDE inhibitors, which are milder than
emesis with cilomilast (14) and central nervous system
effects with rolipram (15), suggesting its appropriateness for
cancer treatment and chemoprevention. Our study intended
to determine the effects of apremilast in cancer with mutated
KRAS (in vivo and in vitro). For this reason, we performed
3D floating culture and nude mice assays using the HKe3
cells overexpressing wild type (wt) PDE4B2, mutated (mt)
PDE4B2 (kinase dead) mtKRAS and wtKRAS. Our results
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suggest that apremilast may be an effective treatment for
human colorectal cancer.
Materials and Methods
Antibodies and reagents. Antibody to cleaved caspase-3 (5A1),
cleaved caspase-7 (D6H1), cleaved poly (ADP-ribose) polymerase
(PARP) (Asp214; D64E10) and caspase-1 were obtained from Cell
Signaling Technology (Beverly, MA, USA). Antibody to actin was
obtained from Sigma-Aldrich (St. Louis, MO, USA). Apremilast
was a kind gift from Celgene Corp, NJ, USA.
Retroviral production and generation of stable cell line. Dasher
Green Fluorescent Protein (DGFP) cDNA from DNA2.0's Cas9
vectors (pD1401-AD) was subcloned into a pMSCVpuro vector
(Clontech, Palo Alto, CA, USA) at a multi-cloning site to generate
retrovirus vector to produce a pMSCV-DGFP vector. cDNAs for
Hemagglutinin (HA)-tagged human wtPDE4B2 (wtPDE4B2-HA)
and HA-tagged human mtPDE4B2 (H234S, mt PDE4B2-HA) were
inserted into the pMSCV-DGFP vector at multi-cloning sites to
generate the mammalian expression plasmids pMSCV-wtPDE4B2-
HA-DGFP and pMSCV-mtPDE4B2-HA-DGFP, which were
produced by the transfection of the retrovirus vectors together with
the pAmpho vector (Clontech) into GP2-293 packaging cells
(Clontech) by standard calcium phosphate transfection in the
presence of 25 μM chloroquine (Sigma-Aldrich). After 48 hours
since transfection, the viral supernatants were collected and
supplemented with 8 μg/ml polybrene (Sigma-Aldrich). The HKe3
cells in six-well plates were infected with the viruses by being spun
for 2 h at 32˚C and 1,000 × g. At 48 h after infection, the cells were
treated with 2 μg/ml puromycin (Sigma-Aldrich) for 1 week to
establish HKe3-derived cells stably expressing wtPDE4B2 or
mtPDE4B2. The cells were further maintained in the medium
containing 2 μg/ml puromycin.
Cell culture. Cells were cultured in Dulbecco's modified Eagle's
medium (DMEM)-high glucose supplemented with 10% fetal
bobine serum and 1% penicillin/streptomycin in the presence or
absence of apremilast (100 μM) for 6 days in two-dimensional (2D)
or 3D culture as previously described (10, 16-23).
Cell growth assay in 2D culture. Herein, 4×104 cells for HKe3-
wtPDE4B2, HKe3-mtPDE4B2 and HKe3-wtKRAS, and 1×104 cells
for HKe3-mtKRAS cells, which were established earlier (23), were
seeded in a 96-well microplate (product number CLS3596; Corning
Inc., Corning, NY, USA) at 37˚C for six days, and the absorbance
of formazan solutions was measured using a 3-(4,5-dimethlthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay-based Cell
Counting Kit-8 (Dojindo, Kumamoto, Japan) according to the
supplier’s instructions. The relative growth rate was calculated from
a comparison of the absorbance obtained from cells treated with
dimethyl sulfoxide (DMSO) alone as a vehicle control.
3D floating cell culture. Cells were seeded in a 96-well plate with
an ultra-low attachment surface and a round bottom (product
number 7007; Corning Inc., Corning, NY, USA). Cells were
cultured for 6 days with or without apremilast in a CO2 incubator,
as previously described (23). Photomicrographs of cells were taken
and analysed using an IN Cell Analyzer 1000 (GE Healthcare, Little
Chalfont, UK) and IN Cell Developer Toolbox (GE Healthcare).
The relative growth rate was calculated from a comparison of the
area of control spheroids at day three.
Quantification of apoptotic cells in spheroids. Apoptotic cells were
stained with Magic Red Caspase 3&7 Assay Kit (ImmunoChemistry
Technologies, LLC, Bloomington, MN, USA) on day 6, according
to the supplier’s instructions, and imaged using CS-SP5 laser
scanning confocal microscopy (Leica, Wetzlar, Germany). The
number of apoptotic cells in spheroids was counted as previously
described (10, 18).
Assay for tumourigenicity. Four-week-old female SHO mice (Crl:
HA-PrkdcscidHrhr) were purchased from Charles River Laboratories
(Yokohama, Japan). Cells for implantation were trypsinised and re-
suspended in a 1:1 mix of phosphate-buffered saline and Matrigel
(BD Bioscience, Bedford, MA, USA). 100 μl containing either
1.5×106 HKe3-mtKRAS or 1×107 of HKe-3-wtPDE4B2, HKe-3-
mtPDE4B2 or HKe3-wtKRAS cells was subcutaneously injected
into the flank of mice. At the beginning of apremilast treatment, the
average diameter of these tumours was approximately 5 mm.
Apremilast was intraperitoneally administered from day 0 to day 7
daily. Tumour volumes were calculated using the formula: (L×W2)
×0.5, where L was the tumour length and W the tumour width. The
tumour volume at day n was expressed as the relative tumour
volume (RTV) and calculated according to the following formula:
RTV=TVn/TV0, where TVn was the tumour volume at day n and
TV0 the tumour volume at day 0. Animal studies were conducted
in accordance with our institutional guidelines, and the experimental
procedures were approved by the Fukuoka University Animal Care
Committee (approval number 1611991).
Immunoblotting. Cells treated with or without apremilast were lysed
in a RIPA buffer [(50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% NP-
40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulphate and
protease inhibitor cocktail) (Roche, Basel, Switzerland)] and were
subjected to immunoblotting as previously described (10, 24).
Quantitative analysis of the immunoblotting was performed using
ImageJ software (National Institute of Health, Bethesda, MD, USA).
Statistical analyses. Data are presented as means±standard
deviations. Statistical analyses were performed using unpaired two-
tailed Student’s t-test. p-Values of less than 0.05 were considered
statistically significant.
Results
Induction of luminal apoptosis by apremilast in HKe3-
wtPDE4B2 and HKe3-mtKRAS cells grown in 3D culture. To
address the effects of apremilast on cell proliferation in 3D
culture, cells were treated with apremilast or DMSO alone.
No significant differences were observed in the growth rates
between HKe3-wtPDE4B2 cells, HKe3-mtPDE4B2 cells or
HKe3-wtKRAS cells treated with apremilast and those
treated with DMSO (Figure 1A). Interestingly, however, the
relative growth rate of HKe3-mtKRAS cells treated with
apremilast was lower than in those treated with DMSO alone
(Figure 1A), suggesting that apremilast, via its inhibitory
action on PDE4, regulates the signalling pathway altered by
mutated KRAS in 3D culture.
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Figure 1. Luminal apoptosis was induced by apremilast in human colorectal cancer HKe3 cells stably expressing wild-type phosphodiesterase 4B2
(PDE4B2) (HKe3-wtPDE4B2) and mutant Kirsten rat sarcoma viral oncogene homologue (KRAS) (HKe3-mtKRAS) cells grown in 3D culture. A:
Relative growth rates of HKe3-wtPDE4B2, HKe3-mutant (mt) PDE4B2, HKe3-wtKRAS and HKe3-mtKRAS with or without apremilast treatment
in 3D culture at day 6. B, C: Left panels: The signals for cleaved caspase-3/7 in HKe3-wtPDE4B2 and HKe3-mtPDE4B2 cells (B) and HKe3-
wtKRAS and HKe3-mtKRAS (C) treated with dimethyl sulfoxide alone (control) or apremilast at day 6 in 3D culture. Cleaved caspase-3/7, red.
Dasher GFP, green. Dots represent luminal cavities. Scale bar=100 μm. Right panels: Number of apoptotic cells in single spheroids. *Significantly
different at p<0.05; n.s., not significant. 
To address whether the influence of apremilast extended
to luminal apoptosis in 3D culture, we evaluated the
apoptotic activity in these cells grown in 3D culture for 6
days by evaluating cleaved caspase-3/7 using confocal
microscopy. In HKe3-wtPDE4B2 control cells, the number
of apoptotic cells was 4.23-fold lower compared to HKe3-
mtPDE4B2 control cells (Figure 1B; p<0.05), suggesting
that the overexpression of wtPDE4B2 was able to inhibit
luminal apoptosis, whereas mtPDE4B2 (kinase dead) was
not. In HKe3-wtPDE4B2 cells treated with apremilast, the
number of apoptotic cells increased 3.38-fold in comparison
to the DMSO control (Figure 1B; p<0.05). In addition to
increased apoptosis, a luminal cavity was observed in cells
treated with apremilast, suggesting that apremilast directly
inhibits the effect of wtPDE4B2. In HKe3-mtPDE4B2 cells,
no significant difference was observed between DMSO
control and apremilast-treated cells (Figure 1B), suggesting
that apremilast acts in this system by inhibiting the PDE
activity of PDE4B2. The signals for dasher GFP representing
the localisation of wtPDE4B2 or mtPDE4B2 were similar,
suggesting that PDE4B2 localisation was not affected by
PDE4B2 mutation (Figure 1B). These results suggest that
apremilast induces luminal apoptosis in colon cancer cells
by inhibiting the activity of PDE4B2.
In HKe3-mtKRAS control cells, the number of apoptotic
cells decreased 3.08-fold in comparison with HKe3-wtKRAS
control cells (Figure 1C; p<0.05), suggesting that the
overexpression of mtKRAS was able to inhibit luminal
apoptosis, whereas that of wtKRAS was not. In HKe3-
mtKRAS cells treated with apremilast, the number of
apoptotic cells increased 3-fold in comparison with DMSO
alone (Figure 1C; p<0.05), suggesting that apremilast
directly counteracts the oncogenic effects of mtKRAS. In
HKe3-wtKRAS cells, no significant difference was observed
between DMSO control and apremilast (Figure 1C),
suggesting that apremilast targets signaling downstream of
mtKRAS, possibly affecting cAMP dynamics orchestrated by
PDE4B2. The data presented here suggests that apremilast
may represent a new therapeutic avenue for colon cancer as
the PDE4 inhibitor induces luminal apoptosis by inhibiting
the activity of PDE4B2.
Apremilast inhibits growth of tumours expressing wtPDE4B2
and mtKRAS in nude mice. For HKe3-wtPDE4B2 cells,
tumour volume experienced a 2.65-fold increase in
comparison to those in HKe3-mtPDE4B2 from day 0 to day
8 (Figure 2A and B), suggesting that wtPDE4B2 promotes
tumour growth in vivo. Tumour volume was dramatically
reduced in HKe3-wtPDE4B2 tumours in mice treated with
apremilast in comparison to those administered DMSO alone
(Figure 2A). In contrast, no difference was observed between
HKe3-mtPDE4B2 cell tumours treated with apremilast and
DMSO controls (Figure 2B), suggesting that apremilast acts
via PDE4 inhibition activity in vivo. In HKe3-mtKRAS cells,
tumour volume increased 9.04-fold in comparison with that
in HKe3-wtKRAS from day 0 to day 8 (Figure 2C and D).
Tumour volume of HKe3-mtKRAS tumours treated with
apremilast was dramatically reduced than in those treated
with DMSO controls (Figure 2D); conversely, no difference
was observed between apremilast-treated mice with HKe3-
wtKRAS tumours and DMSO-treated controls (Figure 2C),
suggesting that apremilast induces apoptosis by inhibiting
the activity of PDE4B2 regulated by mtKRAS in vivo.
mtKRAS and PDE4B2 prevent apoptosis through downr-
egulation of caspase-1. In order to understand the underlying
signaling events regulated by PDE4B2 in a 3D environment,
caspases were examined by immunoblotting in cells from 2D
and 3D culture (Figure 3). In 3D culture, the amount of
cleaved capase-3, caspase-7 and PARP were detected
robustly in HKe3-wtKRAS and HKe3-mtPDE4B2 cells and
were decreased in HKe3-mtKRAS or HKe3-wtPDE4B2
cells, suggesting that mtKRAS and PDE4B2 are involved in
the inhibition of luminal apoptosis in 3D culture.
Surprisingly, the expression of full-length caspase-1 was
strongly increased by wtKRAS and mtPDE4B2 and was
reduced by mtKRAS and wtPDE4B2 in 3D culture,
suggesting that mtKRAS and PDE4B2 down-regulate the
protein expression of caspase-1.
Discussion
In this study, we demonstrated for the first time that the
recently approved PDE4 inhibitor apremilast significantly
promoted apoptosis of HKe3-mtKRAS and HKe3-
wtPDE4B2 cells via a signalling route that includes
PDE4B2 and caspase-1. Our previous work showed that
mtKRAS prevents luminal apoptosis via the induction of
PDE4B2 in HCT116 cells (18), and PDE4B2 inhibitors,
including rolipram and resveratrol, induce luminal
apoptosis (10, 11) by a previously undefined signalling
route. Apremilast is known to be highly specific for PDE4
and mediates its effects in monocytes and T-cells via
protein kinase A (PKA) and nuclear factor kappa B
pathways (13). PDE4 is the predominant cAMP-degrading
enzyme expressed in inflammatory cells in diseases, such
as psoriasis (25). The most common downstream effector
of cAMP is PKA (26), and PKA action can result in up-
regulation of caspase-1 expression (27). Hence, it is logical
to suggest that regulation of cAMP dynamics by PDE4B
could appropriately regulate local PKA activity to affect
caspase-1 expression. Our results showed that PDE4B and
mtKRAS down-regulate the expression of caspase-1 and
promote tumour growth (Figures 2 and 3). In agreement
with this result, recent work has shown that caspase-1-
deficient mice demonstrate increased colonic epithelial cell
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proliferation in early stages of injury-induced tumour
formation and reduced apoptosis in advanced tumours (28).
Furthermore, recent reports also suggest that caspase-7 and
not caspase-3 is activated by caspase-1 in vitro and in vivo
(29, 30), and caspase-7 is a substrate of caspase-1 that
cleaves PARP (31). In our study, the expression changes of
caspase-7 by mtKRAS or PDE4B were larger than those of
caspase-3 (Figure 3). These results together suggest that
mtKRAS and PDE4B are protective against apoptosis by
blocking the caspase-1–caspase-7 axis. We also propose
that caspase-1 signalling may offer novel downstream
targets for apremilast which underpin the mechanism
driving apoptosis of colon cancer cells. Further elucidation
of the molecular mechanisms triggered by novel PDE4
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Figure 2. Assays of in vivo tumourigenicity for human colorectal cancer HKe3 cells. HKe3 cells stably expressing wild-type phosphodiesterase 4B2
(PDE4B2) (HKe3-wtPDE4B2) (A), mutant PDE4B2 (HKe3-mtPDE4B2) (B), wild-type Kirsten rat sarcoma viral oncogene homologue (KRAS)
(HKe3-wtKRAS) (C) and mutant KRAS (HKe3-mtKRAS) (D) were injected subcutaneously into the flanks of nude mice. Relative tumour volumes
are shown for mice treated with and without apremilast.
inhibitors (32) such as apremilast, which drives apoptosis
or pyroptosis is required to bolster the notion that PDE4
inhibition is a future therapeutic avenue for the treatment
of cancer.
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